About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Speaker: Herena Eixarch Ahufinger, Postdoctoral researcher Clinical Neuroimmunology. Vall Hebron Institut de Recerca (VHIR).
Abstract: Multiple sclerosis (MS) is an autoimmune disease that causes demyelination and neurodegeneration. A major unmet need in MS treatment is the development of therapies that restore immune tolerance to self-antigens. Our group have explored an innovative approach using phosphatidylserine liposomes that mimic apoptotic bodies and carry a myelin peptide. In an experimental autoimmune encephalomyelitis (EAE) model, these liposomes demonstrated therapeutic efficacy both before and after symptom onset, through clinically relevant administration routes such as intravenous injection. The mechanism involves expansion of regulatory T and B cells and suppression of MOG-specific inflammatory responses. This strategy offers a safe, versatile, and promising path toward clinical translation in MS.
Online: https://gencat.zoom.us/j/81253478057
